Abstract:Purpose MYCN amplification plays a critical role in defining high-risk subgroup of patients with neuroblastoma. We aimed to develop and validate the CT-based machine learning models for predicting MYCN amplification in pediatric abdominal neuroblastoma. Methods A total of 172 patients with MYCN amplified (n = 47) and non-amplified (n = 125) were enrolled. The cohort was randomly stratified sampling into training and testing groups. Clinicopathological parameters and radiographic features were selected to construct the clinical predictive model. The regions of interest (ROIs) were segmented on three-phrase CT images to extract first-, second- and higher-order radiomics features. The ICCs, mRMR and LASSO methods were used for dimensionality reduction. The selected features from the training group were used to establish radiomics models using Logistic regression, Support Vector Machine (SVM), Bayes and Random Forest methods. The performance of four different radiomics models was evaluated according to the area under the receiver operator characteristic (ROC) curve (AUC), and then compared by Delong test. The nomogram incorporated of clinicopathological parameters, radiographic features and radiomics signature was developed through multivariate logistic regression. Finally, the predictive performance of the clinical model, radiomics models, and nomogram was evaluated in both training and testing groups. Results In total, 1,218 radiomics features were extracted from the ROIs on three-phrase CT images, and then 14 optimal features, including one original first-order feature and eight wavelet-transformed features and five LoG-transformed features, were identified and selected to construct the radiomics models. In the training group, the AUC of the Logistic, SVM, Bayes and Random Forest model was 0.940, 0.940, 0.780 and 0.927, respectively, and the corresponding AUC in the testing group was 0.909, 0.909, 0.729, 0.851, respectively. There was no significant difference among the Logistic, SVM and Random Forest model, but all better than the Bayes model (p <0.005). The predictive performance of the Logistic radiomics model based on three-phrase is similar to nomogram, but both better than the clinical model and radiomics model based on single venous phase. Conclusion The CT-based radiomics signature is able to predict MYCN amplification of pediatric abdominal NB with high accuracy based on SVM, Logistic and Random Forest classifiers, while Bayes classifier yields lower predictive performance. When combined with clinical and radiographic qualitative features, the clinics-radiomics nomogram can improve the performance of predicting MYCN amplification.

Predicting amplification of MYCN using CpG methylation biomarkers in neuroblastoma

Comprehensive analysis and validation reveal potential MYCN regulatory biomarkers associated with neuroblastoma prognosis

CT-Based Radiomics Signature With Machine Learning Predicts MYCN Amplification in Pediatric Abdominal Neuroblastoma

Prediction of MYCN Amplification, 1p and 11q Aberrations in Pediatric Neuroblastoma via Pre-therapy 18F-FDG PET/CT Radiomics

Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in neuroblastoma

Identification of novel prognostic markers of survival time in high-risk neuroblastoma using gene expression profiles

A signature based on five immune-related genes to predict the survival and immune characteristics of neuroblastoma

Construction of methylation driver gene-related prognostic signature and development of a new prognostic stratification strategy in neuroblastoma

Quantification of MYCN, DDX1, and NAG Gene Copy Number in Neuroblastoma Using a Real-Time Quantitative PCR Assay

Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma

A MYCN-independent mechanism mediating secretome reprogramming and metastasis in MYCN -amplified neuroblastoma

Bioinformatic Identification of Neuroblastoma Microenvironment-Associated Biomarkers with Prognostic Value

Identification and validation of a novel five-gene signature in high-risk MYCN-not-amplified neuroblastoma

Altered methylation of imprinted genes in neuroblastoma: implications for prognostic refinement

Supplementary Figure S6 G-K from Drugging MYCN Oncogenic Signaling Through the MYCN-PA2G4 Binding Interface

A Pilot Study of Relating MYCN-Gene Amplification with Neuroblastoma-Patient CT Scans

NCAPG is a Potential Biomarker for Prognosis of Treatment in Children with High-risk Neuroblastoma

Radiogenomics of Neuroblastoma in Pediatric Patients: CT-based Radiomics Signature in Predicting MYCN Amplification

18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography/computed tomography (PET/CT) imaging of pediatric neuroblastoma: a multi-omics parameters method to predict MYCN copy number category

MYC Drives a Subset of High-Risk Pediatric Neuroblastomas and is Activated Through Mechanisms Including Enhancer Hijacking and Focal Enhancer Amplification.

Abstract 5119: Exploring the relationship between metabolism and the epigenome in MYCN -amplified neuroblastoma